Summit Therapeutics plc Summit Therapeutics Plc : Notice Of Agm
May 03 2018 - 5:15AM
UK Regulatory
TIDMSUMM
Summit Therapeutics plc
("Summit" or the "Company")
Publication of UK Annual Report and Notice of Annual General Meeting
Oxford, UK, and Cambridge, MA, US, 3 May 2018 - Summit Therapeutics plc
(AIM: SUMM, NASDAQ: SMMT), announces that its Annual Report and Accounts
for the year ended 31 January 2018, together with the Notice of Annual
General Meeting have today been sent to shareholders. Copies of both
documents are available on the Company's website, www.summitplc.com.
The Annual General Meeting will be held at 10:00am BST on Thursday, 7
June 2018 at Wax Chandlers' Hall, 6 Gresham Street, London, EC2V 7AD.
UK.
About Summit Therapeutics
Summit is a biopharmaceutical company focused on the discovery,
development and commercialisation of novel medicines for indications for
which there are no existing or only inadequate therapies. Summit is
currently conducting clinical programs focused on the genetic disease,
Duchenne muscular dystrophy, and the infectious disease, Clostridium
difficile infection. Further information is available at
www.summitplc.com and Summit can be followed on Twitter (@summitplc).
For more information, please contact:
Summit
Glyn Edwards / Richard Pye (UK office) Tel: 44 (0)1235 443 951
Erik Ostrowski / Michelle Avery (US office) +1 617 225 4455
Cairn Financial Advisers LLP (Nominated
Adviser) Tel: +44 (0)20 7213 0880
Liam Murray / Tony Rawlinson
N+1 Singer (Joint Broker) Tel: +44 (0)20 7496 3000
Aubrey Powell / Jen Boorer
Panmure Gordon (Joint Broker) Tel: +44 (0)20 7886 2500
Freddy Crossley, Corporate Finance
MacDougall Biomedical Communications (US) Tel: +1 781 235 3060
Karen Sharma ksharma@macbiocom.com
Consilium Strategic Communications (UK) Tel: +44 (0)20 3709 5700
Mary-Jane Elliott / Jessica Hodgson / summit@consilium-comms.com
Philippa Gardner / Lindsey Neville
-END-
This announcement is distributed by Nasdaq Corporate Solutions on behalf
of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the information
contained therein.
Source: Summit Therapeutics plc via Globenewswire
http://www.summitplc.com/
(END) Dow Jones Newswires
May 03, 2018 05:15 ET (09:15 GMT)
Copyright (c) 2018 Dow Jones & Company, Inc.
Summit Therapeutics (LSE:SUMM)
Historical Stock Chart
From Apr 2024 to May 2024
Summit Therapeutics (LSE:SUMM)
Historical Stock Chart
From May 2023 to May 2024